Breast cancer: PET and MR predict chemotherapy's ability to prolong life

June 11, 2013

For patients with advanced breast cancer, positron emission tomography (PET) and magnetic resonance (MR) imaging can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, say researchers presenting at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.

Researchers combined separate imaging systems—PET, MR and CT—to map the course of chemotherapy before surgery, otherwise known as . These different imaging systems provide complementary information, both physiological and structural, about how chemotherapy will be distributed in the body to kill breast cancer and . In this study, scientists used a specialized molecular imaging agent called F-18 fluorodeoxyglucose (FDG) that acts as a for with PET in order to pick up on areas of cancer proliferation.

"Previous studies have shown that, separately, FDG PET and dynamic enhanced MR imaging can provide a prediction of how patients will respond to neoadjuvant treatment, but we have improved upon this concept by combining the two techniques side by side," said Sang Moo Lim, MD, current director of the department of nuclear medicine, and until 2006, director of the National Radiation Emergency Medical Center of the Korea Institute of Radiological and Medical Sciences in Seoul, Korea. "Using both FDG PET and MR imaging to predict -free survival allows us to apply more aggressive therapies that could potentially halt patients' cancers and extend their lives."

This study evaluating survival after chemotherapy included a patient population of 44 women with . All underwent three cycles of neoadjuvant chemotherapy and sequential whole-body FDG PET/CT, breast MR and delayed breast PET/CT a total of four times—once prior to the first course of chemotherapy, again after the first course, following the second course and one more time prior to surgery to predict and confirm disease-free survival. Results of the study indicated that patient survival with no recurrence of cancer after neoadjuvant chemotherapy was anywhere from just under three months to about three years for a median of 661 days.

"Additionally, this study demonstrates the collective potential of these imaging systems, which provides evidence that fused PET/MR utilizing both metabolic and vascular perfusion imaging can benefit patients," said Lim. "Together these techniques can help clinicians classify patients and provide risk stratification to not only predict cancer recurrence after treatment but also avoid chemotherapy for those who probably would benefit more from an alternative treatment."

This research using combined, sequential PET and MR imaging provides additional proof of the potential benefit of simultaneous PET/, an emerging molecular imaging technology.

"This extends beyond just breast cancer," Lim added. "We could potentially apply these technologies to other malignancies and develop some brilliant methods to improve clinical outcomes. Considering the results of our research, we now need to further develop the technology—not just imaging systems, but tracers and biomarkers—to advance our field. Research and development in nuclear medicine and can satisfy these demands for the future."

Breast cancer is the world's leading cancer among women–accounting for 16 percent of cancers in females, according to the World Health Organization. The American Cancer Society estimates that one out of every eight American women will develop invasive breast cancer at some point in their lives. According to 2013 statistics, approximately 232,340 new cases of invasive are expected to be diagnosed in women in the United States and as many as 39,620 American women are expected to die from the disease this year.

Explore further: Heart: Cardiac PET/MR measures up to PET/CT

Related Stories

Heart: Cardiac PET/MR measures up to PET/CT

June 10, 2013
Just a few years ago, integrated positron emission tomography and magnetic resonance (PET/MR) imaging was found only in research institutes, but little by little the technology has expanded into clinical practice. This is ...

PET/CT shows clear advantages over conventional staging for breast cancer patients

January 2, 2013
New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic stratification ...

Pretreatment PET/CT imaging of lymph nodes predicts recurrence in breast cancer patients

September 4, 2012
Disease-free survival for invasive ductal breast cancer (IDC) patients may be easier to predict with the help of F-18-fludeoxyglucose positron emission tomography (PET)/computed tomography (CT) scans, according to research ...

Early PET response to neoadjuvant chemo predicts increased survival in sarcoma patients

April 2, 2012
An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers ...

PET predicts outcome of therapy for colorectal cancer patients

June 11, 2012
A study presented at the Society of Nuclear Medicine's 2012 Annual Meeting reveals how molecular imaging biomarkers can be used to approximate howan experimental radiochemotherapy for locally advanced rectal cancer will work. ...

PET techniques provide more accurate diagnosis, prognosis in challenging breast cancer cases

February 6, 2012
In two new studies featured in the February issue of the Journal of Nuclear Medicine, researchers are revealing how molecular imaging can be used to solve mysteries about difficult cases of breast cancer. One article focuses ...

Recommended for you

Clear link between heavy vitamin B intake and lung cancer

August 22, 2017
New research suggests long-term, high-dose supplementation with vitamins B6 and B12—long touted by the vitamin industry for increasing energy and improving metabolism—is associated with a two- to four-fold increased lung ...

Study provides insight into link between two rare tumor syndromes

August 22, 2017
UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation ...

Retaining one normal BRCA gene in breast, ovarian cancers influences patient survival

August 22, 2017
Determining which cancer patients are likely to be resistant to initial treatment is a major research effort of oncologists and laboratory scientists. Now, ascertaining who might fall into that category may become a little ...

Study identifies miR122 target sites in liver cancer and links a gene to patient survival

August 22, 2017
A new study of a molecule that regulates liver-cell metabolism and suppresses liver-cancer development shows that the molecule interacts with thousands of genes in liver cells, and that when levels of the molecule go down, ...

Zebrafish larvae could be used as 'avatars' to optimize personalized treatment of cancer

August 21, 2017
Portuguese scientists have for the first time shown that the larvae of a tiny fish could one day become the preferred model for predicting, in advance, the response of human malignant tumors to the various therapeutic drugs ...

Scientists discover vitamin C regulates stem cell function, curbs leukemia development

August 21, 2017
Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.